Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-00299804 vs erlotinib in advanced non-small cell lung cancer
2010-022656-22Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dacomitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Jun 2011; status: completed.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-022656-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022656-22.